RxDoctor Payments Data

Timber Gorman, MD

Ophthalmology · Trenton, MENPI 1619933215

Payments from drug & device makers

What this record shows

The money is spread across several categories — food and beverage (57.1%), gifts and education — rather than concentrated in one kind of arrangement. Reporting peaked in 2020 at $202 and has fallen 74.4% since, to $52 in 2025.

$396in general payments, 2019–2025

Across 11 payments — averaging $36.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$202
  • Alcon$194

What the payments were for

  • Food & beverage$22657%
  • Education$8020%
  • Gifts$9023%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie7$202
Alcon4$194

How this compares

$396 in reported general payments places this provider in the 55th percentile of 74 ophthalmology providers in Maine.

See all ophthalmology providers in Maine

Medicare billing

Part B allowed, 2024
$308,788
Medicare patients
716
Services billed
4,365

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost73$47,351
XiidraLifitegrast31$44,294
RestasisCyclosporine19$31,458
CombiganBrimonidine Tartrate/Timolol17$10,101
RocklatanNetarsudil Mesylat/Latanoprost11$9,990
Cyclosporine29$9,413
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol20$6,263
Timolol Maleate55$4,946
TobradexTobramycin/Dexamethasone17$4,485
Dorzolamide-TimololDorzolamide/Timolol/Pf13$4,255
Brinzolamide24$4,051
Brimonidine Tartrate35$3,826
Prednisolone Acetate144$3,602
VyzultaLatanoprostene Bunod14$3,514
Ketorolac Tromethamine97$3,309

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Restasis, Combigan$202$88,910109 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 74 ophthalmology providers in Maine.

Other ophthalmology in Trenton

See the full list for Maine

Where these figures come from

Is this you, or does something look wrong? →